GlassScriptPhysician profile
Nisha Vinod Jayani
NPI 1124354584
$1,514.17
in general payments reported to CMS, 2019-2025
19 companies · $176 in 2025
The $176 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $90.41 · 2021: $37.94 · 2022: $746 · 2023: $370 · 2024: $93.50 · 2025: $176.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $640.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $639.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $219.42 | 2022-2025 | Wegovy |
| Astrazeneca Pharmaceuticals LP | $215.49 | 2022 | |
| Horizon Therapeutics Plc | $163.98 | 2022-2023 | Tepezza |
| Mannkind Corporation | $153.11 | 2023 | Afrezza |
| Corcept Therapeutics | $136.80 | 2024-2025 | Korlym |
| Bayer Healthcare Pharmaceuticals INC. | $109.55 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $95.02 | 2023-2025 | Jardiance |
| Ucb, INC. | $63.36 | 2022-2023 | Cimzia |
| Janssen Pharmaceuticals, INC | $55.51 | 2019 | |
| Xeris Pharmaceuticals, INC. | $47.85 | 2023 | Gvoke Hypopen |
| Lilly USA, LLC | $42.93 | 2022-2023 | Mounjaro |
| Insulet Corporation | $34.90 | 2019 | |
| Amgen INC. | $34.15 | 2024 | Repatha |
| Dexcom, INC. | $31.70 | 2022-2023 | Dexcom G6 Transmitter |
| Shionogi INC | $30.65 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lifescan, INC. | $23.84 | 2021 | |
| Medtronic, INC. | $21.00 | 2022 | |
| Tandem Diabetes Care, INC. | $20.81 | 2022 | |
| Abbott Laboratories | $14.10 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nisha Jayani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.